Pubmed uab

UAB can be observed in many neurologic conditions and myogenic failure. Diabetic cystopathy is the most important and inevitable pubmed uab developing from UAB, and can occur silently and early in the disease course.

An International Continence Society Working Group has described UAB as characterised by a slow urinary stream, hesitancy and straining to void, with or without a feeling of incomplete bladder emptying and dribbling, often with storage symptoms. Since DU often coexists with bladder outlet obstruction, or storage dysfunction detrusor overactivity or incontinence , the exact contribution of the DU to the presenting complaints can be difficult to establish. The presence of voiding and post voiding lower urinary tract symptoms LUTS is implicitly expected in UAB, but a reduced sensation of fullness is reported by some patients, and storage LUTS are also an important factor in many affected patients. These may result from a postvoid residual, but often they do not. The storage LUTS are often the key driver in leading the patient to seek healthcare input.

Pubmed uab

.

New concepts such as stem cell therapy and neurotrophic gene therapy are being explored.

.

Lister Hill Library of the Health Sciences. Reynolds-Finley Historical Library. Alabama Museum of the Health Sciences. Lister Hill Library at University Hospital. Ellis Sparks Medical Library. Research Search the Collection Opens a new website. Databases Opens a new website.

Pubmed uab

Don't forget that while searching by MeSH Terms is great for doing focused, relevant searches it may prevent you from seeing any brand new articles that have been published on your topic. Solution: In addition to searching using MeSH Terms, be sure to also run keyword searches for your topic. You can "NOT out" the articles you would have found from a MeSH search so that you don't have to sort through a bunch of duplicates. Here's an example:.

Swimming suit see through

Sacral nerve stimulation may be an effective treatment option for UAB. Scheduled voiding, double voiding, al-blockers, and intermittent self-catheterization are the typical conservative treatment options. Diabetic cystopathy is the most important and inevitable disease developing from UAB, and can occur silently and early in the disease course. The presence of voiding and post voiding lower urinary tract symptoms LUTS is implicitly expected in UAB, but a reduced sensation of fullness is reported by some patients, and storage LUTS are also an important factor in many affected patients. The pharmaceutical and biotechnology industries that have a pipeline in urology and women's health may want to consider UAB as a potential target condition. Keywords: Detrusor underactivity; Lower urinary tract symptoms; Overactive urinary bladder; Underactive bladder. Publication types Review. Qualitative research has established a broad impact on everyday life as a result of these symptoms. Since DU often coexists with bladder outlet obstruction, or storage dysfunction detrusor overactivity or incontinence , the exact contribution of the DU to the presenting complaints can be difficult to establish. Scientific counsel and review of the current pharmaceutical portfolio may uncover agents, including those in other therapeutic fields, that may benefit the management of UAB. Nocturia is particularly common and bothersome, but what the role of DU is in all the range of influences on nocturia has not been established. Proper management is focused on prevention of upper tract damage, avoidance of overdistension, and reduction of residual urine. Careful neurologic and urodynamic examinations are necessary for the diagnosis of UAB. An International Continence Society Working Group has described UAB as characterised by a slow urinary stream, hesitancy and straining to void, with or without a feeling of incomplete bladder emptying and dribbling, often with storage symptoms. New concepts such as stem cell therapy and neurotrophic gene therapy are being explored.

.

Scheduled voiding, double voiding, al-blockers, and intermittent self-catheterization are the typical conservative treatment options. UAB can be observed in many neurologic conditions and myogenic failure. Scientific counsel and review of the current pharmaceutical portfolio may uncover agents, including those in other therapeutic fields, that may benefit the management of UAB. Qualitative research has established a broad impact on everyday life as a result of these symptoms. Proper management is focused on prevention of upper tract damage, avoidance of overdistension, and reduction of residual urine. Nocturia is particularly common and bothersome, but what the role of DU is in all the range of influences on nocturia has not been established. Sacral nerve stimulation may be an effective treatment option for UAB. New concepts such as stem cell therapy and neurotrophic gene therapy are being explored. The pharmaceutical and biotechnology industries that have a pipeline in urology and women's health may want to consider UAB as a potential target condition. Diabetic cystopathy is the most important and inevitable disease developing from UAB, and can occur silently and early in the disease course. Careful neurologic and urodynamic examinations are necessary for the diagnosis of UAB. Keywords: Detrusor overactivity; Diabetic cystopathy; Overactive bladder; Underactive bladder. Keywords: Detrusor underactivity; Lower urinary tract symptoms; Overactive urinary bladder; Underactive bladder.